One-year clinical outcomes of patients implanted with a Resolute Onyx™ zotarolimus-eluting stent

Tam, Chi‐Yung; Chan, Kelvin; Lam, Simon; Yung, Arthur; Lam, Yui Ming; Chan, C. W.; Siu, David; Tse, Hung‐Fat

doi:10.1177/0300060517717826

Cited by 13 publications

(5 citation statements)

References 19 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Technological development led to the introduction of 2.0 mm stents in order to accommodate for smaller vessel size, but the clinical benefit of small stent implantation (≤ 2.25 mm) is vague [55]. The new portfolio of 2.0 mm DES (everolimus-eluting Xience Xpedition SV or Xience Alpine; zotarolimus-eluting Resolute Onyx) created new options of PCI in a smaller vascular territory, with promising results in retrospective analysis [55,56].…”

Section: Bms and Desmentioning

confidence: 99%

Small vessel coronary artery disease: How small can we go with myocardial revascularization?

et al. 2021

View full text Add to dashboard Cite

The issue of small coronary artery atherosclerosis represents an intriguing aspect of coronary artery disease, which is related with higher rates of peri-and post-procedural complications and impaired long-term outcome. This problem is further complicated by the unclear definition of small coronary vessel. Recent randomized controlled trials have provided new data on possible novel interventional treatment of small coronary vessels with drug-coated balloons instead of traditional new-generation drug-eluting stent implantation. Also, the conservative management represents a therapeutic option in light of the results of the recent ISCHEMIA trial. The current article provides an overview of the most appropriate definition, interventional management, and prognosis of small coronary artery atherosclerosis.

show abstract

Section: Bms and Desmentioning

confidence: 99%

Small vessel coronary artery disease: How small can we go with myocardial revascularization?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Regarding the safety and efficacy of O-ZES, O-ZES showed 1-year TLF rate of 4.4% and similar efficacy and safety compared with most contemporary DES [18]. O-ZES demonstrated superiority for 8-month in-stent late lumen loss compared with the historical control R-ZES in the RESOLUTE ONYX core trial (0.24 ± 0.39 mm with O-ZES vs. 0.36 ± 0.52 mm with R-ZES, p = 0.029) [19].…”

Section: Discussionmentioning

confidence: 85%

Comparison of short-term clinical outcomes between Resolute Onyx zotarolimus-eluting stents and everolimus-eluting stent in patients with acute myocardial infarction: Results from the Korea Acute Myocardial infarction Registry (KAMIR)

Kim

Jeong

et al. 2019

Cardiol J.

View full text Add to dashboard Cite

show abstract

“…It is important to highlight that our population was basically constituted by ACS patients when compared to other registries. The risk of adverse events is distinct to patients with stable disease, mainly in relation to mortality [ 11 – 15 ].…”

Section: Discussionmentioning

confidence: 99%

One-Year Clinical Outcome of Inspiron Stent in All-Comers Population (Analysis from 790 Consecutive Patients)

Falcão

Cantarelli

et al. 2020

Journal of Interventional Cardiology

View full text Add to dashboard Cite

Aims. The goal of this study was to evaluate the performance of the InspironTM coronary stent (Scitech Medical™, Goiás, Brazil). The InspironTM sirolimus-eluting stent uses an ultrathin L-605 cobalt-chromium alloy with a 75 μm strut thickness platform coated with an abluminal biodegradable polymer. The polymer is eliminated from the body through the tricarboxylic acid cycle in 6–9 months, releasing 80% of the drug within 30 days after its deployment. Methods. It was a prospective, single-center registry. To represent clinical practice, all patients undergoing percutaneous coronary intervention were included in this registry. There were no exclusion criteria. Clinical follow-ups were performed at twelve months. The endpoints were the occurrence of all-cause death, definite stent thrombosis, and new revascularization. Results. Between November 2017 and May 2019, 790 patients were included (1067 lesions). The mean age was 60.42 ± 14.94 years, and 74.7% presented with acute coronary syndrome. Diabetes mellitus was present in 43.9% of patients, and previous myocardial infarction and previous percutaneous coronary intervention were present in 17.9% and 11.3%, respectively. Angiographic success was achieved in 99.1%. The incidence of all-cause death was 11.5% (6.2% in-hospital and 5.3% in the follow-up) and definitive stent thrombosis was 0.2%. New revascularization was performed in only 5.8% (target lesion revascularization: 2.2%; progression of disease in another lesion: 3.6%). Based on the multivariate regression analysis, only chronic renal failure was an independent predictor of adverse events (OR: 3.3; 95% CI: 1.22–8.92). Conclusion. The result of this single-center registry demonstrates the safety and excellent performance of the InspironTM stent in daily clinical practice with a low rate of adverse cardiac events.

show abstract

One-year clinical outcomes of patients implanted with a Resolute Onyx™ zotarolimus-eluting stent

Cited by 13 publications

References 19 publications

Small vessel coronary artery disease: How small can we go with myocardial revascularization?

Small vessel coronary artery disease: How small can we go with myocardial revascularization?

Comparison of short-term clinical outcomes between Resolute Onyx zotarolimus-eluting stents and everolimus-eluting stent in patients with acute myocardial infarction: Results from the Korea Acute Myocardial infarction Registry (KAMIR)

One-Year Clinical Outcome of Inspiron Stent in All-Comers Population (Analysis from 790 Consecutive Patients)

Contact Info

Product

Resources

About